Artelo Biosciences ARTL shares are trading higher on Tuesday after the company received Ethics Committee approval in the UK to commence its Phase I/II study of ART27.13.
Artelo Biosciences is a United States-based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system.
Artelo Biosciences shares traded up 27.49% to $1.02 on Tuesday during the time of publication. The stock has a 52-week high of $4.42 and a 52-week low of 61 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
